Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2025
  • Page 112
mirum-pharma-and-bluejay-therapeutics-deal-seen-as-boost-to-mirum’s-rare-disease-expertise
Posted inGenetics

Mirum Pharma and Bluejay Therapeutics Deal Seen as Boost to Mirum’s Rare Disease Expertise

December 9, 2025
Mirum Pharmaceuticals signed a definitive agreement to acquire Bluejay Therapeutics, a privately-held biotech company focused on viral and liver diseases.…
Read More
fda-qualifies-1st-ai-drug-development-tool-for-reading-mash-images
Posted inResearch

FDA qualifies 1st AI drug development tool for reading MASH images

December 9, 2025
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical…
Read More
medline-sets-terms-for-massive-$5.37b-nasdaq-ipo
Posted inMedical Technology

Medline sets terms for massive $5.37B Nasdaq IPO

December 9, 2025
Medline has put forward terms for an absolutely massive IPO, which could see the medical device manufacturing and distribution giant…
Read More
sarcopenia-and-osteoporosis:-combined-impact-on-mortality
Posted inBiotechnology

Sarcopenia and Osteoporosis: Combined Impact on Mortality

December 9, 2025
In recent research, the interplay between two age-related conditions—sarcopenia and osteoporosis—has garnered increasing attention within the scientific community. Sarcopenia, characterized…
Read More
ash:-exicure-rebounds-with-phase-2-win,-seeing-90%-blood-cell-mobilization-in-myeloma
Posted inBiotechnology

ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma

December 9, 2025
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple…
Read More
ose-narrows-focus-to-conserve-cash-at-expense-of-wider-pipeline
Posted inBiotechnology

Ose narrows focus to conserve cash at expense of wider pipeline

December 9, 2025
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab…
Read More
pfizer-continues-renewed-obesity-push-with-$150m-upfront-for-fosun-unit’s-glp-1-drug
Posted inBiotechnology

Pfizer continues renewed obesity push with $150M upfront for Fosun unit’s GLP-1 drug

December 9, 2025
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going…
Read More
link-between-hla-class-i-alleles-and-tuberculosis-risk
Posted inBiotechnology

Link Between HLA Class I Alleles and Tuberculosis Risk

December 9, 2025
Tuberculosis (TB) remains one of the most formidable infectious diseases globally, causing millions of deaths each year, primarily in low-income…
Read More
fda-steers-cancer-car-t-developers-toward-randomized-superiority-trials-in-policy-shift
Posted inBiotechnology

FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift

December 9, 2025
The FDA is raising the bar for approval of CAR-T cell therapies in oncology. Under plans outlined by the FDA’s biologics…
Read More
novartis-pens-$1.7b-immuno-dermatology-pact-with-ai-enabled-british-biotech
Posted inBiotechnology

Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech

December 9, 2025
Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology…
Read More

Posts pagination

Previous page 1 … 110 111 112 113 114 … 1,169 Next page

Privacy Policy    Terms

Scroll to Top